{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:24:06Z","timestamp":1762867446880,"version":"3.37.3"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,5,16]],"date-time":"2018-05-16T00:00:00Z","timestamp":1526428800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001827","name":"University of Amsterdam","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001827","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s00108-018-0431-4","type":"journal-article","created":{"date-parts":[[2018,5,16]],"date-time":"2018-05-16T04:28:03Z","timestamp":1526444883000},"page":"560-566","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["IgG4-assoziierte Cholangitis \u2013 klinische Pr\u00e4sentation eines lange \u00fcbersehenen Krankheitsbildes","IgG4-associated cholangitis \u2013 clinical presentation of an overlooked disease entity"],"prefix":"10.1007","volume":"59","author":[{"given":"T.","family":"Herta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Verheij","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Beuers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,5,16]]},"reference":[{"issue":"3","key":"431_CR1","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1053\/j.gastro.2007.12.009","volume":"134","author":"A Ghazale","year":"2008","unstructured":"Ghazale A et al (2008) Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterology 134(3):706\u2013715","journal-title":"Gastroenterology"},{"issue":"Suppl 2","key":"431_CR2","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1159\/000440830","volume":"33","author":"U Beuers","year":"2015","unstructured":"Beuers U et al (2015) IgG4-associated cholangitis\u2014a mimic of PSC. Dig Dis 33(Suppl 2):176\u2013180","journal-title":"Dig Dis"},{"issue":"10","key":"431_CR3","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1038\/ajg.2014.223","volume":"109","author":"MT Huggett","year":"2014","unstructured":"Huggett MT et al (2014) Type 1 autoimmune pancreatitis and IgG4-related sclerosing cholangitis is associated with extrapancreatic organ failure, malignancy, and mortality in a\u00a0prospective UK cohort. Am J Gastroenterol 109(10):1675\u20131683","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"431_CR4","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1056\/NEJMra1104650","volume":"366","author":"JH Stone","year":"2012","unstructured":"Stone JH, Zen Y, Deshpande V (2012) IgG4-related disease. N\u00a0Engl J Med 366(6):539\u2013551","journal-title":"N Engl J Med"},{"issue":"6","key":"431_CR5","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1097\/MPA.0b013e3182480c99","volume":"41","author":"A Kanno","year":"2012","unstructured":"Kanno A et\u00a0al (2012) Nationwide epidemiological survey of autoimmune pancreatitis in Japan. Pancreas 41(6):835\u2013839","journal-title":"Pancreas"},{"issue":"4","key":"431_CR6","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1002\/hep.26999","volume":"60","author":"LJ Maillette de Buy Wenniger","year":"2014","unstructured":"Maillette de Buy Wenniger LJ, Culver EL, Beuers U (2014) Exposure to occupational antigens might predispose to IgG4-related disease. Hepatology 60(4):1453\u20131454","journal-title":"Hepatology"},{"key":"431_CR7","first-page":"646","volume-title":"Immunoglobulin E, eosinophils and mast cells in atopic individuals provide novel insights in IGG4-related disease","author":"E Culver","year":"2016","unstructured":"Culver E et al (2016) Immunoglobulin E, eosinophils and mast cells in atopic individuals provide novel insights in IGG4-related disease Bd. 64, S 646"},{"issue":"6","key":"431_CR8","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/bjs.6057","volume":"95","author":"D Erdogan","year":"2008","unstructured":"Erdogan D et al (2008) Immunoglobulin G4-related sclerosing cholangitis in patients resected for presumed malignant bile duct strictures. Br J Surg 95(6):727\u2013734","journal-title":"Br J Surg"},{"doi-asserted-by":"crossref","unstructured":"(2009) EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J\u00a0Hepatol 51(2):237\u2013267","key":"431_CR9","DOI":"10.1016\/j.jhep.2009.04.009"},{"issue":"3","key":"431_CR10","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1002\/hep.24487","volume":"54","author":"AM Oseini","year":"2011","unstructured":"Oseini AM et al (2011) Utility of serum immunoglobulin G4 in distinguishing immunoglobulin G4-associated cholangitis from cholangiocarcinoma. Hepatology 54(3):940\u2013948","journal-title":"Hepatology"},{"issue":"5","key":"431_CR11","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1002\/hep.26977","volume":"59","author":"K Boonstra","year":"2014","unstructured":"Boonstra K et al (2014) Serum immunoglobulin G4 and immunoglobulin G1 for distinguishing immunoglobulin G4-associated cholangitis from primary sclerosing cholangitis. Hepatology 59(5):1954\u20131963","journal-title":"Hepatology"},{"issue":"1","key":"431_CR12","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1097\/BOR.0b013e3283413469","volume":"23","author":"RP Sah","year":"2011","unstructured":"Sah RP, Chari ST (2011) Serologic issues in IgG4-related systemic disease and autoimmune pancreatitis. Curr Opin Rheumatol 23(1):108\u2013113","journal-title":"Curr Opin Rheumatol"},{"issue":"3","key":"431_CR13","doi-asserted-by":"publisher","first-page":"536","DOI":"10.2214\/AJR.12.10360","volume":"202","author":"A Tokala","year":"2014","unstructured":"Tokala A et al (2014) Comparative MRI analysis of morphologic patterns of bile duct disease in IgG4-related systemic disease versus primary sclerosing cholangitis. AJR Am J Roentgenol 202(3):536\u2013543","journal-title":"AJR Am J Roentgenol"},{"issue":"5","key":"431_CR14","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1148\/rg.315105735","volume":"31","author":"PA Vlachou","year":"2011","unstructured":"Vlachou PA et al (2011) IgG4-related sclerosing disease: autoimmune pancreatitis and extrapancreatic manifestations. Radiographics 31(5):1379\u20131402","journal-title":"Radiographics"},{"issue":"9","key":"431_CR15","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1038\/modpathol.2012.72","volume":"25","author":"V Deshpande","year":"2012","unstructured":"Deshpande V et al (2012) Consensus statement on the pathology of IgG4-related disease. Mod Pathol 25(9):1181\u20131192","journal-title":"Mod Pathol"},{"issue":"10","key":"431_CR16","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1111\/j.1440-1746.2010.06346.x","volume":"25","author":"H Kawakami","year":"2010","unstructured":"Kawakami H et al (2010) IgG4-related sclerosing cholangitis and autoimmune pancreatitis: histological assessment of biopsies from Vater\u2019s ampulla and the bile duct. J\u00a0Gastroenterol Hepatol 25(10):1648\u20131655","journal-title":"J Gastroenterol Hepatol"},{"issue":"6","key":"431_CR17","doi-asserted-by":"publisher","first-page":"2390","DOI":"10.1002\/hep.26232","volume":"57","author":"LJ Maillette de Buy Wenniger","year":"2013","unstructured":"Maillette de Buy Wenniger LJ et al (2013) Immunoglobulin G4+ clones identified by next-generation sequencing dominate the B cell receptor repertoire in immunoglobulin G4 associated cholangitis. Hepatology 57(6):2390\u20132398","journal-title":"Hepatology"},{"issue":"3","key":"431_CR18","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.jaci.2014.03.034","volume":"134","author":"H Mattoo","year":"2014","unstructured":"Mattoo H et al (2014) De novo oligoclonal expansions of circulating plasmablasts in active and relapsing IgG4-related disease. J\u00a0Allergy Clin Immunol 134(3):679\u2013687","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"431_CR19","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1002\/hep.28568","volume":"64","author":"ME Doorenspleet","year":"2016","unstructured":"Doorenspleet ME et al (2016) Immunoglobulin G4(+) B\u2011cell receptor clones distinguish immunoglobulin G 4\u2011related disease from primary sclerosing cholangitis and biliary\/pancreatic malignancies. Hepatology 64(2):501\u2013507","journal-title":"Hepatology"},{"issue":"5","key":"431_CR20","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1002\/hep.21405","volume":"44","author":"R Abdalian","year":"2006","unstructured":"Abdalian R, Heathcote EJ (2006) Sclerosing cholangitis: a\u00a0focus on secondary causes. Hepatology 44(5):1063\u20131074","journal-title":"Hepatology"},{"issue":"6","key":"431_CR21","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1053\/j.gastro.2013.10.013","volume":"145","author":"S Rizvi","year":"2013","unstructured":"Rizvi S, Gores GJ (2013) Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology 145(6):1215\u20131229","journal-title":"Gastroenterology"},{"issue":"2\u20133","key":"431_CR22","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1007\/s12016-014-8430-2","volume":"48","author":"LM Hubers","year":"2015","unstructured":"Hubers LM et al (2015) IgG4-associated cholangitis: a\u00a0comprehensive review. Clin Rev Allergy Immunol 48(2\u20133):198\u2013206","journal-title":"Clin Rev Allergy Immunol"},{"issue":"4","key":"431_CR23","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1111\/j.1365-2222.2009.03207.x","volume":"39","author":"RC Aalberse","year":"2009","unstructured":"Aalberse RC et\u00a0al (2009) Immunoglobulin G4: an odd antibody. Clin Exp Allergy 39(4):469\u2013477","journal-title":"Clin Exp Allergy"},{"issue":"8","key":"431_CR24","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1136\/gutjnl-2015-310336","volume":"65","author":"M Shiokawa","year":"2016","unstructured":"Shiokawa M et al (2016) Pathogenicity of IgG in patients with IgG4-related disease. Gut 65(8):1322\u20131332","journal-title":"Gut"},{"issue":"6","key":"431_CR25","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1002\/art.27435","volume":"62","author":"A Khosroshahi","year":"2010","unstructured":"Khosroshahi A et al (2010) Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4-related systemic disease. Arthritis Rheum 62(6):1755\u20131762","journal-title":"Arthritis Rheum"},{"issue":"4","key":"431_CR26","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1136\/gutjnl-2017-314548","volume":"67","author":"LM Hubers","year":"2017","unstructured":"Hubers LM et al (2017e) Annexin A11 is targeted by IgG4 and IgG1 autoantibodies in IgG4-related disease. Gut 67(4):728. \n                    https:\/\/doi.org\/10.1136\/gutjnl-2017-314548","journal-title":"Gut"},{"issue":"11","key":"431_CR27","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1111\/j.1398-9995.2008.01774.x","volume":"63","author":"F Meiler","year":"2008","unstructured":"Meiler F et al (2008) Distinct regulation of IgE, IgG4 and IgA by T regulatory cells and toll-like receptors. Allergy 63(11):1455\u20131463","journal-title":"Allergy"},{"issue":"8","key":"431_CR28","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/nri1412","volume":"4","author":"TA Wynn","year":"2004","unstructured":"Wynn TA (2004) Fibrotic disease and the T(H)1\/T(H)2 paradigm. Nat Rev Immunol 4(8):583\u2013594","journal-title":"Nat Rev Immunol"},{"issue":"7","key":"431_CR29","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1002\/art.39132","volume":"67","author":"A Khosroshahi","year":"2015","unstructured":"Khosroshahi A et al (2015) International consensus guidance statement on the management and treatment of IgG4-related disease. Arthritis Rheumatol 67(7):1688\u20131699","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"431_CR30","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1097\/MPA.0000000000000044","volume":"43","author":"J Buijs","year":"2014","unstructured":"Buijs J et al (2014) Comparable efficacy of low- versus high-dose induction corticosteroid treatment in autoimmune pancreatitis. Pancreas 43(2):261\u2013267","journal-title":"Pancreas"},{"issue":"6","key":"431_CR31","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1136\/annrheumdis-2014-206605","volume":"74","author":"MN Carruthers","year":"2015","unstructured":"Carruthers MN et al (2015) Rituximab for IgG4-related disease: a\u00a0prospective, open-label trial. Ann Rheum Dis 74(6):1171\u20131177","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"431_CR32","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/jhbp.50","volume":"21","author":"A Tanaka","year":"2014","unstructured":"Tanaka A et al (2014) Nationwide survey for primary sclerosing cholangitis and IgG4-related sclerosing cholangitis in Japan. J\u00a0Hepatobiliary Pancreat Sci 21(1):43\u201350","journal-title":"J Hepatobiliary Pancreat Sci"},{"issue":"3","key":"431_CR33","doi-asserted-by":"publisher","first-page":"414","DOI":"10.3109\/s10165-011-0520-x","volume":"22","author":"M Yamamoto","year":"2012","unstructured":"Yamamoto M et al (2012) Risk of malignancies in IgG4-related disease. Mod Rheumatol 22(3):414\u2013418","journal-title":"Mod Rheumatol"},{"issue":"5","key":"431_CR34","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1097\/MPA.0b013e31819d73ca","volume":"38","author":"N Takahashi","year":"2009","unstructured":"Takahashi N et al (2009) Possible association between IgG4-associated systemic disease with or without autoimmune pancreatitis and non-Hodgkin lymphoma. Pancreas 38(5):523\u2013526","journal-title":"Pancreas"},{"key":"431_CR35","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1159\/000213364","volume":"79","author":"YA Alderlieste","year":"2009","unstructured":"Alderlieste YA, van den Elzen BDJ, Rauws EAJ, Beuers U (2009) Immunoglobulin G4-Associated cholangitis: one variant of immunoglobulin G4-related systemic disease. Digestion 79:220\u2013228","journal-title":"Digestion"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00108-018-0431-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-018-0431-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-018-0431-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,15]],"date-time":"2019-05-15T21:35:13Z","timestamp":1557956113000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00108-018-0431-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,16]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["431"],"URL":"https:\/\/doi.org\/10.1007\/s00108-018-0431-4","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"type":"print","value":"0020-9554"},{"type":"electronic","value":"1432-1289"}],"subject":[],"published":{"date-parts":[[2018,5,16]]},"assertion":[{"value":"16 May 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"T.\u00a0Herta und J.\u00a0Verheij geben an, dass kein Interessenkonflikt besteht. U.\u00a0Beuers: Forschungsunterst\u00fctzung von deutschen (DCCV), norwegischen, amerikanischen und s\u00fcdafrikanischen PSC-Patientenstiftungen sowie von der niederl\u00e4ndischen Magen-Leber-Darm-Stiftung. Vortragshonorare von AbbVie, Falk Foundation, Gilead, Intercept, Novartis, Roche, Shire, Zambon. Beratungshonorare von Intercept, Novartis. Studienunterst\u00fctzung (\u201einvestigator-initiated\u201c) von Dr. Falk, Intercept.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Dieser Beitrag beinhaltet keine von den Autoren durchgef\u00fchrten Studien an Menschen oder Tieren.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}]}}